Published in Cancer Weekly, June 24th, 2003
Responses extending beyond the 4-year-mark are described with the average duration in 34% of the patients that had a complete response to Zevalin (vs. 16% in the control group) currently approaching 2 years. The updated trial results are based on a pivotal clinical trial that included 143 patients randomized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.